Memorial Sloan Kettering Posts $339.1M Operating Income Through Q3
Memorial Sloan Kettering Cancer Center reported operating income of $339.1 million (4.9% margin) for the nine months ended Sept. 30, 2026, reversing an operating loss of $174.9 million (-2.8% margin) in the same period last year, per its Nov. 13 financial report. Total operating revenue rose to $7 billion from $6.2 billion, aided by higher patient revenue, $57.3 million in COVID-19 relief funding, and $35.9 million in settlement payments. Operating expenses grew to $6.6 billion from $6.4 billion, driven mainly by personnel and pharmaceutical costs after excluding one-time EHR go-live costs from the prior year. Medicaid accounted for 4% of patient revenue, down from 6%, while commercial payers rose to 63% and Medicare to 32%; net income totaled $1.1 billion, up from $296.8 million.